Research progress in the roles and mechanisms of DLC2 in tumor
10.3969/j.issn.1001-1978.2019.07.006
- Author:
Xiao-Man LI
1
Author Information
1. School of Pharmacy, Nanjing University of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
CeRNA;
DLC2;
RhoGAP;
STARD13;
Tumor suppressor;
Tumorigenesis and progression
- From:
Chinese Pharmacological Bulletin
2019;35(7):911-914
- CountryChina
- Language:Chinese
-
Abstract:
DLC2( Deleted in liver cancer 2), a newly discovered tumor suppressor, was deleted or under-expressed in many tumors, such as in liver cancer, breast cancer and glioma. DLC2 could enhance the activity of GTPase of RhoA and Cdc42, negatively regulate the activity of Rho protein and the downstream signal molecules, and target focal adhesion; DLC2 could react with other proteins via its SAM domain, inducing the protein ubiquitination and degradation; recendy, studies have re-ported that DLC2 and other transcription could regulate each oth-er's level via ceRNA mechanism. Based on the above mechanisms , DLC2 suppresses tumor proliferation, promotes tumor ap-optosis, blocks tumor metastasis, invasion and adhesion, decreases the sternness of tumor cells and enhances drug sensitivity of tumor cells. Therefore, over-expression of DLC2 could be a potential antitumor strategy.
